Clearside Biomedical (NASDAQ: CLSD) is one of 296 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare Clearside Biomedical to related businesses based on the strength of its analyst recommendations, valuation, dividends, earnings, risk, profitability and institutional ownership.

Insider & Institutional Ownership

52.5% of Clearside Biomedical shares are owned by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 20.9% of Clearside Biomedical shares are owned by insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Clearside Biomedical has a beta of -11.74, indicating that its stock price is 1,274% less volatile than the S&P 500. Comparatively, Clearside Biomedical’s competitors have a beta of 6.58, indicating that their average stock price is 558% more volatile than the S&P 500.


This table compares Clearside Biomedical and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Clearside Biomedical -27,225.52% -65.78% -53.90%
Clearside Biomedical Competitors -5,449.71% -442.49% -42.04%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Clearside Biomedical and its competitors, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Clearside Biomedical 0 0 5 0 3.00
Clearside Biomedical Competitors 767 3061 11246 227 2.71

Clearside Biomedical currently has a consensus target price of $20.00, indicating a potential upside of 180.90%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 35.66%. Given Clearside Biomedical’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Clearside Biomedical is more favorable than its competitors.

Valuation and Earnings

This table compares Clearside Biomedical and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Clearside Biomedical $144,999.00 -$38.44 million -4.24
Clearside Biomedical Competitors $263.26 million $68.25 million -6.41

Clearside Biomedical’s competitors have higher revenue and earnings than Clearside Biomedical. Clearside Biomedical is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

About Clearside Biomedical

Clearside Biomedical, Inc. is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment. With its microinjector, drugs are injected into and spread within and through the suprachoroidal space, (SCS), which is the space located between the choroid and the outer protective layer of the eye known as the sclera. With the suprachoroidal injection, its product candidates are more directly administered to the retina and choroid as compared to other ocular drug administration techniques, such as injections of drug into the vitreous, a jelly-like substance that occupies the central portion of the eye.

Receive News & Ratings for Clearside Biomedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc. and related companies with's FREE daily email newsletter.